NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, NEW ZEALAND, SOUTH AFRICA, HONG KONG, SINGAPORE OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR OTHER MEASURES.

Lund, Sweden – April 17, 2019 – BioInvent International AB (“BioInvent” or the “Company”) (OMXS: BINV) today announces that the new share issue with preferential rights for existing shareholders has been completed. A total of approximately MSEK 98.7, corresponding to 46.9 per cent of the rights issue, was subscribed for with subscription rights. A total of approximately MSEK 1.4, corresponding to 0.7 per cent of the rights issue, was subscribed for without subscription rights and the remaining part of the rights issue, corresponding to approximately MSEK 110.4 or 52.4 per cent of the total proceeds, was subscribed for by guarantors.

Shares subscribed for without subscription rights have been allotted in accordance with the principles stated in the prospectus prepared in connection with the new share issue and published on 21 March 2019. Notice of the allotment of shares subscribed for without subscription rights will today be sent to those who have been allotted shares.

In parallel with the rights issue, and as previously announced, BioInvent has carried out a directed issue of MSEK 30 to a Swedish Pension Fund and a Swedish life science fund. The directed issue was conducted at the same subscription price as the rights issue. The rights issue and the directed issue together provide BioInvent with approximately MSEK 240 before transaction costs. Jointly, the new share issues entail that the Company’s share capital increases by SEK 12,023,999.04, to a total of SEK 40,087,996.80 and the number of shares by 150,299,988, to a total of 501,099,960 when the rights issue is registered with the Swedish Companies Registration Office (the directed issue has already been registered). Trading in the new shares issued through the rights issue is expected to take place on or around 3 May 2019.

Martin Welschof, CEO of BioInvent, says: “This capital raise was mandatory to open up further opportunities for BioInvent, in particular for accelerating the development of our high-quality pipeline developed using our unique F.I.R.S.T.TM platform. This includes moving exciting pre-clinical programs into clinical stage and further advancing our first-in-class clinical candidate, and we will also continue to focus on partnering opportunities for our product candidates as well as our technology platform. We are looking forward to the opportunity to deliver medical solutions to meet patient needs and generate value for our shareholders.”

Financial and legal advisers
Pareto Securities AB is acting as financial advisor and Mannheimer Swartling Advokatbyrå AB is acting as legal advisor to BioInvent. 

About BioInvent
BioInvent International AB (OMXS: BINV) is focused on the discovery and development of novel and first-in-class immuno-modulatory antibodies to treat cancer. The Company’s lead program BI-1206, is currently in Phase l/ll for non-Hodgkin lymphoma and chronic lymphatic leukemia. BioInvent’s pre-clinical portfolio is focused on targeting key immune suppressive cells and pathways of the tumor microenvironment, including regulatory T cells, tumor-associated myeloid cells and mechanisms of antibody drug-resistance. The Company has a strategic research collaboration with Pfizer Inc., and partnerships with Transgene, Bayer Pharma, Daiichi Sankyo, and Mitsubishi Tanabe Pharma. BioInvent generates near term revenues from its fully integrated manufacturing unit producing antibodies for third parties for research through to late-stage clinical trials. More information is available at www.bioinvent.com.

BioInvent International AB (publ)
Co. Reg. No. Org nr: 556537-7263
Visiting address: Sölvegatan 41
Mailing address: 223 70 LUND
Phone: +46 (0)46 286 85 50
www.bioinvent.com

Important information
The information in this press release does not contain or constitute an offer to acquire, subscribe or otherwise trade in shares or other securities in BioInvent International AB. Any invitation to the persons concerned to subscribe for shares in BioInvent has only been made through the prospectus that was published on 21 March 2019.

The information in this press release may not be released, published or distributed, directly or indirectly, in or into the United States (including its territories and provinces, every state in the United States and the District of Columbia), Australia, Hong Kong, Japan, Canada, New Zeeland, Singapore or South Africa or any other jurisdiction in which such action is subject to legal restrictions or would require other measures than those required by Swedish law.

This press release does not contain or constitute an offer to acquire or subscribe to securities in the United States. No subscription rights, BTAs (interim shares) or shares have or will be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or the securities legislation of any state or other jurisdiction in the United States may not be offered, subscribed, sold or otherwise transferred, directly or indirectly, in or within the United States, other than pursuant to an exemption from, or in a transaction that is not subject to, the registration requirements under the U.S. Securities Act and in accordance with the securities legislation in the relevant state or any other jurisdiction of the United States. BioInvent does not intend to register any portion of the offering of the securities in the United States or to conduct a public offering in the securities in the United States.

No public offering of securities is made to any country within the European Economic Area (the “EEA”) other than Sweden. In other member states of the EEA which have implemented European Parliament and Council Directive 2003/71/EC (the “Prospectus Directive”), such offering may be made only under the exemption in the Prospectus Directive as well as every relevant implementation measure (including measures to implement European Parliament and Council Directive 2010/73/EU).

The press release contains statements about the future, consisting of subjective assumptions and forecasts for future scenarios. Predictions for the future only apply as the date they are made and are, by their very nature, in the same way as research and development work in the biotech segment, associated with risk and uncertainty. With this in mind, the actual outcome may deviate significantly from the scenarios described in this press release.